Suspension of trading
Biotest AG Stock Deutsche Boerse AG
Stocks
BIO3
DE0005227235
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.20 EUR | +1.34% |
|
+1.34% | +13.53% |
| 06-15 | Biotest GmbH & Co. KGaA announces Annual dividend, payable on July 24, 2026 | CI |
| 03-25 | Biotest GmbH & Co. KGaA Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Market Cap | 1.31B 1.5B 1.21B 1.13B 2.12B 141B 2.14B 14.35B 5.56B 69.56B 5.62B 5.5B 242B | P/E 2024 * |
-
| P/E 2025 | -17.7x |
|---|---|---|---|---|---|
| Enterprise Value | 2.05B 2.35B 1.9B 1.78B 3.33B 222B 3.35B 22.5B 8.72B 109B 8.82B 8.63B 379B | EV / Sales 2024 * |
-
| EV / Sales 2025 | 3.36x |
| Free-Float |
28.77% | Yield 2024 * |
-
| Yield 2025 | 0.13% |
| 1 week | +1.34% | ||
| 1 month | +1.34% | ||
| 3 months | +4.50% | ||
| 6 months | +16.15% | ||
| Current year | +13.53% |
| 1 week | 29.6 |  | 30.2 |
| 1 month | 29.6 | | 30.2 |
| 3 years | 23 | | 36.3 |
| 5 years | 19.85 | | 43.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jörg Schüttrumpf
CEO | Chief Executive Officer | 52 | 2025-05-27 |
Oliver Hein
CMP | Compliance Officer | - | 2016-12-31 |
Christian Polus
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | 2022-05-04 | |
Dirk Schuck
BRD | Director/Board Member | 47 | 2022-04-05 |
David Ian Bell
BRD | Director/Board Member | 72 | 2022-05-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.34% | +1.34% | +14.83% | -15.17% | 1.5B | |
| +0.33% | -0.36% | +18.76% | -22.11% | 62.05B | |
| +0.20% | -9.17% | +58.39% | +196.56% | 54.52B | |
| -3.92% | +37.40% | +37.40% | +37.40% | 41.55B | |
| +7.62% | +8.19% | -51.27% | -59.11% | 39.06B | |
| -1.05% | -1.73% | +55.35% | -33.92% | 29.02B | |
| +3.50% | +28.15% | +151.81% | -50.31% | 25.38B | |
| -0.78% | -9.50% | +43.87% | +55.34% | 19.62B | |
| +1.74% | -0.39% | -2.93% | +113.90% | 16.89B | |
| -0.05% | +0.23% | +61.48% | +101.93% | 15.89B | |
| Average | +0.84% | +2.77% | +38.77% | +32.45% | 33.78B | |
| Weighted average by Cap. | +0.78% | +1.72% | +36.56% | +35.80% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 726M 833M 673M 630M 1.18B 78.59B 1.19B 7.98B 3.09B 38.68B 3.13B 3.06B 134B | 649M 744M 601M 563M 1.06B 70.22B 1.06B 7.13B 2.76B 34.57B 2.79B 2.73B 120B |
| Net income | 26.4M 30.28M 24.45M 22.89M 42.93M 2.86B 43.19M 290M 112M 1.41B 114M 111M 4.88B | -70.7M -81.09M -65.48M -61.3M -115M -7.65B -116M -777M -301M -3.77B -304M -298M -13.08B |
| Net Debt | 552M 633M 512M 479M 898M 59.77B 903M 6.07B 2.35B 29.42B 2.38B 2.33B 102B | 742M 851M 687M 643M 1.21B 80.28B 1.21B 8.15B 3.16B 39.51B 3.19B 3.13B 137B |
Employees
-
Sector
Pharmaceuticals
Calendar
07-22 -
Ex-dividend date - 0.04 EUR
Net sales - Rate of surprise
- Stock Market
- Stocks
- BIO0 Stock
- BIO3 Stock
Select your edition
All financial news and data tailored to specific country editions
